CONZIP Drug Patent Profile

When do Conzip patents expire, and what generic alternatives are available?

Conzip is a drug marketed by Cipher Pharms Inc and is included in one NDA.

The generic ingredient in CONZIP is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Conzip

A generic version of CONZIP was approved as tramadol hydrochloride by SUN PHARM INDS INC on June 19^th, 2002.

Summary for CONZIP

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	94
Clinical Trials:	1
Patent Applications:	2,442
Drug Prices:	Drug price information for CONZIP
What excipients (inactive ingredients) are in CONZIP?	CONZIP excipients list
DailyMed Link:	CONZIP at DailyMed

See drug prices for CONZIP

Recent Clinical Trials for CONZIP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 2

See all CONZIP clinical trials

Pharmacology for CONZIP

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

US Patents and Regulatory Information for CONZIP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-001	May 7, 2010		RX	Yes	Yes
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-003	May 7, 2010		RX	Yes	No
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-004	Aug 1, 2011		DISCN	Yes	No
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-002	May 7, 2010		RX	Yes	No

Expired US Patents for CONZIP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-001	May 7, 2010	7,858,118
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-002	May 7, 2010	7,858,118
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-003	May 7, 2010	7,858,118

International Patents for CONZIP

See the table below for patents covering CONZIP around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004110410
Australia	2002337967	EXTENDED RELEASE COMPOSITION CONTAINING TRAMADOL
Canada	2495463	COMPOSITION A LIBERATION MODIFIEE CONTENANT DU TRAMADOL (EXTENDED RELEASE COMPOSITION CONTAINING TRAMADOL)

Supplementary Protection Certificates for CONZIP

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0566709	SPC/GB04/012	United Kingdom		PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
0566709	C300152	Netherlands		PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405

CONZIP Market Analysis and Financial Projection

Tramadol Market Dynamics and Financial Trajectory: A Focus on CONZIP

Introduction to Tramadol and CONZIP

Tramadol, marketed under various brand names including CONZIP, is an opioid analgesic used to treat moderate to moderately severe pain in adults. CONZIP, specifically, is an extended-release formulation of tramadol, designed to provide prolonged analgesic effects.

Market Size and Forecast

The global tramadol market, which includes CONZIP, was valued at USD 5.26 billion in 2022 and is projected to reach USD 7.29 billion by 2030, growing at a CAGR of 4.41% from 2023 to 2030[1].

Drivers of the Tramadol Market

Several factors are driving the growth of the tramadol market, including:

Increasing Prevalence of Chronic Pain

Chronic pain is a significant health concern affecting a large portion of the population. Tramadol, with its efficacy in managing chronic pain, is a key driver of this market[1].

Growing Geriatric Population

The aging population is more prone to chronic pain and other age-related conditions that require pain management medications. As this population grows, so does the demand for tramadol[1].

Global Demand for Effective Pain Management

There is a rising global demand for effective pain management drugs that offer long-lasting relief. Tramadol's lower risk of addiction compared to other opioids makes it a preferred choice[1].

Market Segmentation

The tramadol market is segmented based on several criteria:

By Application

• Hospital Pharmacy: This segment accounted for a significant revenue share in 2021 due to the increasing number of inpatient admissions for chronic pain management.
• Retail Pharmacy: A traditional channel for drug distribution.
• Online Pharmacy: Expected to grow at the fastest CAGR due to increased internet usage and accessibility of tramadol[1].

By Dosage Form

• Tablet: The tramadol tablet segment, which includes CONZIP, held the largest market share in 2023. This is due to its high efficacy, ease of manufacturing, and convenience of dosing and administration[4].
• Capsule: An alternative for patients who have difficulty swallowing tablets.

By Geography

• Europe: Expected to maintain a major stake in the global tramadol market due to high healthcare expenditure and favorable government initiatives for opioid substitution therapy.
• Asia Pacific: Anticipated to see lucrative growth driven by improving healthcare infrastructure, rising disposable incomes, and increasing awareness about pain management in countries like China and India[1].

Market Dynamics

Drivers

• Regulatory Approvals: Innovations in formulations and regulatory approvals from agencies like the FDA, WHO, and EMA enhance market accessibility and demand[4].
• Expanding Distribution Channels: The proliferation of online pharmacies and more internet drug shopping contribute to market growth[1].

Restraints

• Stringent Regulatory Restrictions: Tramadol is closely monitored due to its potential for abuse and dependence, which can hinder market growth[4].
• Competition from Alternatives: Competition from other pain management drugs can also impact the market[4].

Opportunities

• Emerging Markets: Countries like China and India offer substantial growth opportunities due to their large and diverse patient populations[4].
• Innovations in Drug Delivery Systems: Advances in drug delivery systems and the adoption of digital health solutions are shaping the future of the market[4].

Financial Trajectory

The financial trajectory of the tramadol market, including CONZIP, is promising:

• Market Size: Expected to grow from USD 5.26 billion in 2022 to USD 7.29 billion by 2030[1].
• CAGR: Projected to grow at a CAGR of 4.41% from 2023 to 2030[1].
• Revenue Growth: Another report indicates that the global tramadol market revenue is expected to grow at a CAGR of 6.86% from 2024 to 2030, reaching nearly USD 6.75 billion by 2030[4].

Key Players

Major players in the tramadol market include:

• Pfizer Inc.
• J&J Innovative Medicine
• Teva Pharmaceuticals
• GSK plc These companies leverage their extensive distribution networks and strong R&D capabilities to maintain a competitive advantage[4].

Regional Insights

Europe

Europe is expected to maintain a significant share in the global tramadol market due to high healthcare expenditure, favorable government initiatives, and the prevalence of chronic pain and back pain[1].

Asia Pacific

The Asia Pacific region is witnessing rapid growth driven by improving healthcare infrastructure, rising disposable incomes, and increasing awareness about pain management. Countries like China and India are key markets[1].

Impact of Regulatory Frameworks

Regulatory frameworks play a crucial role in the tramadol market. For instance, the FDA and other regulatory bodies closely monitor tramadol due to its potential for abuse and dependence. This monitoring helps in gaining the trust of healthcare providers and patients towards the product[4].

Challenges and Risks

Addiction and Misuse

Tramadol, despite its lower risk of addiction compared to other opioids, still poses risks of physical dependence and tolerance. Long-term misuse can lead to severe health consequences, including liver and kidney damage, hormonal imbalances, and mental health disorders[5].

Legal and Financial Implications

Misuse of tramadol can result in legal consequences and significant financial difficulties, impacting personal and professional life[5].

Key Takeaways

• The tramadol market, including CONZIP, is driven by the increasing prevalence of chronic pain, the growing geriatric population, and global demand for effective pain management.
• The market is segmented by application, dosage form, and geography, with Europe and the Asia Pacific being key regions.
• Regulatory approvals and expanding distribution channels are significant drivers, while stringent regulatory restrictions and competition from alternatives are restraints.
• The market is expected to grow at a CAGR of 4.41% from 2023 to 2030, reaching USD 7.29 billion by 2030.
• Major players like Pfizer Inc., J&J Innovative Medicine, and Teva Pharmaceuticals dominate the market.

Frequently Asked Questions

1. What is the current market size of the tramadol drug market?

The tramadol drug market was valued at USD 5.26 billion in 2022[1].

2. What is the projected growth rate of the tramadol market?

The tramadol market is projected to grow at a CAGR of 4.41% from 2023 to 2030[1].

3. Which regions are expected to see significant growth in the tramadol market?

Europe and the Asia Pacific are expected to see significant growth, with Europe maintaining a major stake and the Asia Pacific witnessing rapid growth due to improving healthcare infrastructure and rising disposable incomes[1].

4. What are the main drivers of the tramadol market?

The main drivers include the increasing prevalence of chronic pain, the growing geriatric population, and the global demand for effective pain management drugs[1].

5. What are the potential risks associated with long-term use of tramadol?

Long-term use of tramadol can lead to physical dependence, tolerance, chronic constipation, hormonal imbalances, liver and kidney damage, and mental health disorders[5].

Cited Sources:

1. Verified Market Research - Tramadol Drug Market Size, Share, Trends, Growth And Forecast[1].
2. Minnesota Opioid Settlement Expenditure Reporting Project - Minnesota Opioid Settlement Expenditure Reporting Project[2].
3. SAGE Journals - An insight into the sale of prescription drugs and medicine on the dark web[3].
4. Stellar Market Research - Tramadol Market: Global Industry Analysis and Forecast (2024-2030)[4].
5. The Grove Estate - Tramadol Addiction: Understanding and Recovery[5].